Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTC

Brief Summary:

This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of pembrolizumab, pralatrexate and decitabine.

For participation and/or eligibility criteria, visit website provided below.


Sponsor: University of Virginia


Merck Sharp & Dohme LLC

Otsuka Pharmaceutical Development & Commercialization, Inc.

Contacts and Locations

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03240211

Contact: Marian Abdelmalek, MS 434-924-8827

Contact: Justin Alicea 434-243-5350


Participating Locations:

Emily Couric Clinical Cancer Center
Charlottesville, VA, United States
Principal Investigator
Enrica Marchi, MD
Marian Abdelmalek, MS